全球周邊血管內碎石術（IVL）市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球血管內碎石市場報告

2025年全球血管內碎石術市場規模為3.35億美元。在預測期內，該市場預計將以23.3%的複合年成長率成長，到2032年將達到14億美元。

本報告對全球血管內雷射消融術（IVL）市場進行了詳細分析，包括銷售量、手術量、平均售價、市場規模、市場佔有率、成長趨勢和市場預測。報告中還說明了市場促進因素和限制因素、近期併購、公司概況、產品系列和主要企業。儘管與更廣泛的周邊血管器械市場相比，IVL 仍是一個相對狹窄的細分市場，但其在鈣化病變治療中日益重要的臨床意義以及在複雜血管內治療中不斷擴大的作用，使其成為成長最快的細分市場之一。

血管內碎石術（IVL）因其能夠在最大限度減少血管壁損傷的同時精準清除鈣化灶而備受關注。這項特性使其成為血管準備至關重要的手術，或傳統球囊擴張、支架置入或動脈粥狀硬化斑塊切除術不適用或無效的手術中的理想選擇。隨著醫生對該技術的理解不斷加深以及臨床數據的不斷積累，IVL正從一種新興的治療方式發展成為鈣化治療的成熟方案。

儘管成長勢頭強勁，但高成本仍限制市場發展。與動脈粥狀硬化斑塊切除術裝置相比，取石球囊的售價要高得多。此外，高昂的資本投入成本可能會使該技術的普及更具選擇性，尤其是在醫療機構中，手術量必須足以證明投資的合理性。然而，適應症的擴大和醫生認知度的提高正在逐步消除部分障礙，從而推動靜脈內碎石術（IVL）市場的快速成長。

市場概覽

• 全球血管內碎石市場涵蓋了基於導管的裝置，這些裝置旨在利用球囊擴張前或擴張過程中局部聲壓波來擊碎血管內的鈣化組織。這項技術旨在解決嚴重鈣化問題，這是血管內治療最具挑戰性的問題之一。在鈣化病變中，標準球囊可能無法充分擴張，支架可能無法正確貼附，而動脈粥狀硬化斑塊切除術會增加手術的複雜性和風險。血管內碎石術（IVL）提供了一種替代病灶治療方法，其重點在於改善鈣化，同時最大限度地減少對周圍組織的損傷。

由於鈣化性周邊動脈和冠狀動脈疾病仍然是臨床上面臨的主要挑戰，市場正在快速成長。隨著患者族群老化以及糖尿病、腎臟病和其他心血管危險因子的持續流行，高度鈣化病變的負擔不斷加重。這些患者通常需要更先進的病變形成工具，因此迫切需要能夠使治療更安全、更可預測的技術。

IVL市場也反映了血管內治療精準化的大趨勢。醫師越來越傾向於採用能夠改善手術控制、減少併發症並促進良好術後效果的病灶形成技術。在此背景下，IVL因其能夠與其他治療手段相容，並能無縫整合到現有工作流程中，而備受關注。

另一方面，與較成熟的血管治療領域相比，該市場仍處於相對集中且發展初期。強勁的臨床需求、不斷擴大的應用場景以及有限的競爭是靜脈注射溶栓（IVL）預計到2032年將快速成長的主要原因。

市場促進因素

強而有力的臨床證據

全球血管內碎石術 (IVL) 市場最重要的促進因素之一是現有臨床證據的充分性。隨著多項臨床試驗的完成和更多研究的開展，IVL 已累積了充分的臨床支持，有助於醫生了解該技術在哪些情況下以及如何有效應用。對於這個相對較新且價格較高的醫療設備類別而言，強力的證據至關重要，因為它可以減少醫生的猶豫，並增強他們在改變治療方案時的信心。

臨床證據也透過幫助新用戶熟悉這項技術，推動了市場擴張。對於不太熟悉靜脈內雷射消融術（IVL）的醫生而言，系統性試驗數據支援該設備的安全性、手術效用和解剖學相容性。這不僅鼓勵醫生直接採用該技術，也提高了介入醫學界對該技術的認知。

擴大臨床選擇

另一個主要的成長要素是臨床選擇的擴展。血管內震波碎石術（IVL）在周邊血管、冠狀動脈和膝下區域的應用日益廣泛，顯著提升了其在血管介入治療中的重要性。 IVL不再局限於特定的專科手術，而是被應用於更廣泛的病變類型和解剖區域。

這一點至關重要，因為每增加一個應用案例，商業性合理性就會增加一分。隨著醫院和醫生團隊熟練在多種手術中使用靜脈注射技術，推廣這項技術變得更加容易。此外，手術數量的增加意味著有更多機會累積證據、完善最佳實踐，並發現更多適用的應用情境。臨床領域的拓展是市場快速成長最有力的原因之一。

支援EVAR和TAVR手術

血管內震波碎石術（IVL）也受惠於其在血管內主動脈修復術（EVAR）和經導管主動脈瓣置換術術（TAVR）中日益廣泛的應用。這些手術通常需要可靠的股動脈入路，因為它們經常使用大尺寸（F1）器械。對於髂動脈或股動脈鈣化的患者，入路可能困難或風險較高。 IVL 正逐漸成為解決此類病例入路的重要工具，它能夠最大限度地減少血管應力並降低鈣化引起的阻力。

EVAR 和 TAVR 均為高價值手術，成功建立血管通路至關重要，因此血管內震波碎石術 (IVL) 成為重要的市場促進因素。隨著 IVL 在這些手術中的應用日益廣泛，該技術的重要性已從治療周邊病變擴展到結構性及主動脈介入治療流程。這進一步提升了該市場在手術領域的重要性。

市場限制

昂貴的技術

全球血管內碎石術（IVL）市場最大的限制因素是技術成本。與動脈粥狀硬化斑塊切除術裝置相比，碎石球囊的價格要高得多。除了單一球囊的價格外，資本投資成本也會影響該技術的普及。希望控制每次手術成本效益的醫療機構可能會限制其使用範圍，尤其是在實施初期。因此，有些診所往往只有在有足夠的病例來證明投資的合理性時才會考慮採用這項技術。

隨著適應症範圍的不斷擴大和IVL技術支援更多產品類型，部分障礙將會得到緩解。然而，每個球囊的高成本仍然是一個主要考慮因素。在許多醫療機構中，即使臨床價值明確，經濟因素也會影響產品的使用頻率以及接受治療的患者群體。

競爭加劇

另一個重要的限制因素是來自於動脈動脈粥狀硬化斑塊切除術日益激烈的競爭，尤其是在臨床檢查室和其他對成本敏感的環境中。在周邊血管領域擁有廣泛產品系列的大型公司正積極尋求動脈粥狀硬化斑塊切除術的壟斷地位，並經常利用這種地位在同一醫療機構內擴大其他產品的銷售。由於血管內雷射消融術（IVL）也針對鈣沉積，因此儘管其技術機制不同，但兩者在應對類似的臨床挑戰方面存在競爭關係。

在門診環境中，經濟因素、合作協議以及醫生對設備的熟悉程度都會對設備的選擇產生重大影響，因此這種競爭尤其顯著。雖然靜脈內雷射消融術（IVL）在某些病灶中可能具有明顯的臨床優勢，但如果醫療機構已經採用其他斑塊清除策略，其應用仍可能受到限制。

基於經濟因素的選擇性使用

靜脈溶栓（IVL）市場也受到此技術應用選擇性而非普遍性的限制。即使在已實施IVL技術的醫療機構中，臨床醫生也可能僅在鈣負荷嚴重到足以抵消其成本的情況下才使用該技術。換言之，市場成長不僅取決於醫療機構是否能夠獲得該技術，還取決於醫生使用該技術的頻率。這種選擇性使用模式可能會減緩技術的普及速度，即使在醫生認知度不斷提高的市場中也是如此。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性研究範圍

市場促進因素和限制因素、市場規模和成長趨勢、近期併購、公司簡介、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料：截至 2022 年，預測：截至 2032 年。

按地區定位

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區、非洲。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告旨在透過將定價和銷售量分析與實際臨床和市場條件相結合，為策略規劃、競爭基準分析和商業性評估提供支援。

目標市場及區隔

本報告涵蓋全球血管內碎石市場。

競爭分析

2024年5月，強生公司完成了Shockwave Medical的收購，進一步鞏固了強生醫療科技在介入心臟病學領域的領先地位。此交易具有重要的戰略意義，因為Shockwave Medical是靜脈衝擊波碎石術（IVL）市場的唯一競爭對手，也是該領域的先驅。

Shockwave Medical 的旗艦產品－末梢用血管切開取石球囊擴張導管，於 2016 年 9 月首次獲得 FDA核准用於周邊血管。此後，該公司透過臨床開發、拓展適應症和加強醫生教育，不斷擴大市場佔有率。其重點臨床項目包括針對股膕動脈的 DISRUPT II 和 III 試驗，以及評估近端血管內碎石術 (IVL) 的 DISRUPT BTK 和 BTK II 試驗。 2019 年 9 月，Shockwave 的碎石球囊也獲得 FDA核准用於冠狀動脈，進一步拓展了公司的業務範圍，並鞏固了 IVL 作為多功能技術的地位。

Shockwave Medical 已在該領域站穩腳跟，其業績與整體市場擴張密切相關。其優勢不僅在於早期進入市場，還在於累積了可靠的實證醫學證據、拓展了適應症，並提高了介入治療領域對靜脈內震波碎石術 (IVL) 的認知度。隨著強生醫療科技 (Johnson & Johnson MedTech) 收購該平台，該領域有望受益於更廣泛的商業性覆蓋率以及與全球心血管產品組合更緊密的整合。

目前，競爭格局仍高度集中。這與較成熟的血管器械領域相比有所不同，但也反映出血管內雷射消融術（IVL）領域尚處於發展初期，以及競爭對手之間為實現差異化而採取的策略。

技術與臨床實務的趨勢

血管內碎石術（IVL）市場最顯著的趨勢之一是，在複雜病灶中擴大採用體外碎石術去除鈣化灶。醫生們日益認知到，IVL 可以在改善血管順應性的同時，最大限度地減少對血管壁的傷害。

另一個重要趨勢是血管內震波碎石術（IVL）在各解剖區域的應用範圍不斷擴大。雖然其在周圍血管的應用仍然佔據主導地位，但冠狀動脈和膝下區域的應用也正在推動市場擴張。此外，在經導管主動脈瓣置換術術（EVAR）和經導管主動脈瓣置換術（TAVR）前使用血管內震波碎石術也成為臨床上的新趨勢。

臨床工作流程的整合也不斷推進。隨著醫生在血管內雷射消融術（IVL）方面累積經驗，這項技術正自然地融入病變管理策略中，與球囊、支架和其他輔助工具一起使用。

最後，提供可靠的證據仍然是市場發展的核心。持續的研究不斷影響醫師的認知，並拓展了靜脈注射溶栓術（IVL）作為適當有效治療方案的臨床應用範圍。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球分析。

一份詳盡的 48 頁市場分析、預測和特定類別見解。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

全球血管內碎石術市場中最具發展前景的領域在哪裡？

周邊血管、冠狀動脈和膝下血管手術適應症的擴大將如何影響長期需求？

IVL 在 EVAR 和 TAVR 手術準備中發揮什麼作用？這個機會有多重要？

高昂的價格和設備投資成本如何影響醫院、診所檢查室和其他醫療機構的採用？

競爭格局的集中程度如何？強生公司收購 Shockwave Medical 對該領域意味著什麼？

到 2032 年，臨床證據、醫生意識以及對鈣管理的需求將如何影響市場成長？

iData Research 的《全球血管內碎石市場報告》透過詳盡的市場規模、定價分析、競爭格局資訊和預測模型，解答了這些問題。利用這份報告，您可以評估市場機遇，衡量產業成長，並在血管介入這一複雜領域中成長最快的細分市場之一制定策略。

目錄

圖表清單

圖表列表

調查方法

• 第一步：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

血管內碎石市場

• 執行摘要
  • 全球血管內碎石術市場概況。
  • 競爭分析
  • 目標程式
  • 目標區域
• 介紹
• 手術次數
• 市場分析與預測
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Intravascular Lithotripsy Market Report

The global intravascular lithotripsy market was valued at $335 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 23.3% to reach $1.4 billion by 2032.

This report provides focused analysis of the global IVL market, including unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and market forecasts. It also includes detailed discussion of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. Although the category remains relatively narrow compared with broader peripheral vascular device markets, IVL is one of the fastest-growing segments due to its clinical relevance in calcified lesions and its expanding role in complex endovascular intervention.

Intravascular lithotripsy is gaining traction because it offers a targeted way to modify calcium while minimizing trauma to the vessel wall. This makes it especially attractive in procedures where vessel preparation matters and where conventional ballooning, stenting or atherectomy may be less desirable or less effective. As physicians become more familiar with the technology and as supporting clinical data expands, IVL is moving from a newer niche treatment into a more established option for calcium management.

Despite this strong growth profile, the market is still shaped by high cost. Relative to atherectomy devices, lithotripsy balloons sell at a substantial premium. Capital costs can also make adoption more selective at the account level, particularly in care settings where procedure volumes need to justify the investment. Even so, expanding indications and growing physician awareness are gradually reducing some of these barriers, helping support the rapid rise of the IVL market.

Market Overview

• The global intravascular lithotripsy market includes catheter-based devices designed to fracture vascular calcium through localized sonic pressure waves before or during balloon dilation. The technology was developed to address one of the most difficult challenges in endovascular intervention: severe calcification. In calcified lesions, standard balloons may not fully expand, stents may not appose properly and atherectomy may carry added procedural complexity or risk. IVL offers an alternative method of lesion preparation that focuses on modifying calcium while limiting damage to surrounding tissue.

This market has grown quickly because calcified peripheral and coronary disease remains a major clinical challenge. As patient populations age and as diabetes, renal disease and other cardiovascular risk factors remain prevalent, the burden of heavily calcified lesions continues to rise. These patients often require more advanced lesion preparation tools, which creates a strong need for technologies that can make treatment safer and more predictable.

The IVL market also reflects a broader movement toward precision-based endovascular care. Physicians increasingly want lesion preparation technologies that improve procedural control, reduce complications and support better downstream outcomes. In this setting, IVL has gained attention because it addresses calcium in a way that is compatible with other treatment tools and can often fit smoothly into existing workflows.

At the same time, the market is still relatively concentrated and early in its development compared with more mature vascular categories. That combination of strong clinical need, expanding use cases and limited competitive saturation is a key reason why IVL is projected to grow so quickly through 2032.

Market Drivers

Strong Clinical Evidence

One of the most important drivers in the global intravascular lithotripsy market is the strength of the available clinical evidence. With multiple clinical trials already completed and additional studies ongoing, IVL has built a meaningful body of support that helps physicians understand where and how the technology can be used effectively. For a newer and premium-priced device category, strong evidence is essential because it reduces hesitation and gives clinicians more confidence in changing treatment patterns.

Clinical evidence also supports market expansion by helping newer users become comfortable with the technology. For physicians who are less familiar with IVL, well-structured trial data can validate the safety profile, procedural utility and anatomical compatibility of the device. This not only supports direct adoption but also increases visibility within the broader interventional community.

Expanding Clinical Options

Another major growth driver is the expansion of clinical options. As IVL obtained indications for peripheral, coronary and below-the-knee use, its relevance across vascular intervention increased significantly. Rather than being limited to one procedural niche, IVL can now be considered across a wider range of lesion types and anatomical territories.

This matters because every additional use case improves the commercial logic of adoption. When hospitals or physician groups can use IVL across multiple procedures, the technology becomes easier to justify. More procedures also mean more opportunities to generate evidence, refine best practices and identify further compatible applications. This expanding clinical footprint is one of the strongest reasons why the market is growing at such a high rate.

EVAR and TAVR Procedure Support

IVL is also benefiting from its increasing role in endovascular aortic repair, or EVAR, and transcatheter aortic valve replacement, or TAVR, procedures. These procedures require reliable femoral access to the aorta, often with large French devices. In patients with calcified iliac or femoral arteries, access can be difficult or risky. Because IVL can reduce calcium-related resistance while maintaining low vessel trauma, it is becoming an important access-enabling tool in these cases.

This is a meaningful market driver because EVAR and TAVR are high-value procedures where access success is critical. As IVL use in these procedures grows, it expands the technology's importance beyond peripheral lesion preparation and into structural and aortic intervention workflows. That gives the market another layer of procedural relevance.

Market Limiters

Expensive Technology

The largest limiter in the global IVL market is the cost of the technology. Relative to atherectomy devices, lithotripsy balloons carry a substantial premium. In addition to per-balloon pricing, capital costs can also influence adoption. Care settings that want to control per-procedure economics may limit use to selected cases, especially early in adoption. This makes some clinics hesitant to start using the technology unless volumes are high enough to justify the investment.

As indications continue to expand and as IVL becomes compatible with more procedure types, some of these barriers are reduced. Still, the high cost per balloon remains a major consideration. In many accounts, the clinical value may be clear, but economic evaluation still shapes how often the product is used and which patients receive it.

Increasing Competition

Another important limiter is growing competition, especially from atherectomy devices in office-based labs and other cost-sensitive settings. Large companies with broad peripheral vascular portfolios are increasingly aggressive in pursuing atherectomy exclusivity, often using that position to drive additional product sales across an account. Because IVL also addresses calcium, it competes for a similar clinical problem even if the technologies work differently.

This competition is especially relevant in outpatient settings where economics, portfolio contracting and physician familiarity strongly influence device choice. IVL may offer clear clinical advantages in some lesions, but its adoption can still be constrained if accounts are already aligned around other plaque modification strategies.

Selective Use Driven by Economics

The IVL market is also limited by the fact that the technology is often used selectively rather than universally. Even in accounts that have adopted IVL, clinicians may reserve it for cases where calcium burden is severe enough to justify the cost. That means market growth depends not just on whether a site has access to the technology, but also on how often physicians choose to deploy it. This selective use pattern can slow penetration even in markets where physician awareness is rising.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitive benchmarking and commercial assessment by combining pricing and unit analysis with practical clinical and market context.

Markets Covered and Segmentation

The report covers the Global Intravascular Lithotripsy Market.

Competitive Analysis

In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical, further strengthening Johnson & Johnson MedTech's leadership in cardiovascular intervention. This transaction is strategically important because Shockwave Medical was the sole competitor in the IVL market and the company that established the category.

Shockwave Medical's flagship product, the Peripheral Lithoplasty Balloon Dilation Catheter, first received FDA approval for peripheral use in September 2016. Since then, the company has built the market through clinical development, regulatory expansion and physician education. Key clinical programs have included the DISRUPT II and III trials in the femoral-popliteal artery, as well as the DISRUPT BTK and BTK II trials evaluating IVL below the knee. In September 2019, Shockwave's Lithoplasty balloon also gained FDA approval for coronary use, extending the company's reach and reinforcing IVL as a multi-application technology.

Because Shockwave Medical has effectively defined the category, its commercial performance has been tied closely to overall market expansion. The company's advantage comes not only from being first to market, but also from building strong evidence, widening indications and making IVL more familiar across interventional specialties. With Johnson & Johnson MedTech now owning the platform, the category is positioned to benefit from broader commercial reach and stronger integration into global cardiovascular portfolios.

At present, the competitive landscape remains highly concentrated. This is unusual compared with more mature vascular device categories, but it also reflects how early and differentiated the IVL segment still is.

Technology and Practice Trends

One of the clearest trends in the IVL market is the growing use of lithotripsy for calcium modification in complex lesions. Physicians are increasingly recognizing that IVL can improve vessel compliance while keeping wall trauma relatively low.

Another important trend is the widening use of IVL across different anatomical settings. Peripheral use remains central, but coronary and below-the-knee applications are helping broaden the market. Access support before EVAR and TAVR is another growing practice trend.

Clinical workflow integration is also improving. As physicians gain experience with IVL, the technology is being incorporated more naturally into lesion preparation strategies alongside balloons, stents and other adjunctive tools.

Finally, strong evidence generation remains central to market development. Ongoing studies continue to shape physician perception and expand the set of clinical scenarios where IVL is considered an appropriate and effective treatment option.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

48 pages of detailed market analysis, forecasts and category-level discussion.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the fastest-growing opportunities in the global intravascular lithotripsy market?

How are expanding indications in peripheral, coronary and below-the-knee procedures affecting long-term demand?

What role does IVL play in EVAR and TAVR access preparation, and how important is that opportunity?

How do premium pricing and capital costs affect adoption across hospitals, office-based labs and other care settings?

How concentrated is the competitive landscape, and what does Johnson & Johnson's acquisition of Shockwave Medical mean for the category?

How are clinical evidence, physician awareness and calcium management needs shaping market growth through 2032?

The Global Intravascular Lithotripsy Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, competitive intelligence and forecast modeling. Use it to evaluate opportunity, benchmark category growth and support strategy in one of the fastest-growing segments of complex vascular intervention.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Intravascular Lithotripsy Market

• 8.1 Executive Summary
  • 8.1.1 Global Intravascular Lithotripsy Market Overview
  • 8.1.2 Competitive Analysis
  • 8.1.3 Procedures Included
  • 8.1.4 Regions Included
• 8.2 Introduction
• 8.3 Procedure Numbers
• 8.4 Market Analysis And Forecast
• 8.5 Drivers And Limiters
  • 8.5.1 Market Drivers
  • 8.5.2 Market Limiters
• 8.6 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 8-1: Intravascular Lithotripsy Market, Global, 2025 & 2032
• Chart 8-2: Intravascular Lithotripsy Procedures, Global, 2025
• Chart 8-3: Intravascular Lithotripsy Procedures by Region, Global, 2022 - 2032
• Chart 8-4: Intravascular Lithotripsy Market, Global, 2022 - 2032

LIST OF FIGURES

• Figure 8-1: Intravascular Lithotripsy Procedures Covered
• Figure 8-2: Intravascular Lithotripsy Regions Covered, Global (1 of 2)
• Figure 8-3: Intravascular Lithotripsy Regions Covered, Global (2 of 2)
• Figure 8-4: Intravascular Lithotripsy Procedures by Region, Global, 2022 - 2032
• Figure 8-5: Intravascular Lithotripsy Procedures by Country, North America, 2022 - 2032
• Figure 8-6: Intravascular Lithotripsy Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 8-7: Intravascular Lithotripsy Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 8-8: Intravascular Lithotripsy Procedures by Country, Western Europe, 2022 - 2032
• Figure 8-9: Intravascular Lithotripsy Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 8-10: Intravascular Lithotripsy Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 8-11: Intravascular Lithotripsy Procedures by Country, Middle East, 2022 - 2032
• Figure 8-12: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 8-13: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 8-14: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 8-15: Intravascular Lithotripsy Procedures by Country, Africa, 2022 - 2032
• Figure 8-16: Intravascular Lithotripsy Market, Global, 2022 - 2032
• Figure 8-17: Units Sold by Region, Intravascular Lithotripsy Market, Global, 2022 - 2032
• Figure 8-18: Average Selling Price by Region, Intravascular Lithotripsy Market, Global, 2022 - 2032 (US$)
• Figure 8-19: Market Value by Region, Intravascular Lithotripsy Market, Global, 2022 - 2032 (US$M)
• Figure 8-20: Leading Competitors, Intravascular Lithotripsy Market, Global, 2025